Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)

CAPS Rating: 3 out of 5

A biopharmaceutical company building an oncology business by developing and commercializing innovative therapies that target the molecular mechanisms implicated in cancer.

Results 61 - 69 of 69 : « Previous 1 2 3 4

Recs

1
Member Avatar saintshawn29 (56.89) Submitted: 2/12/2007 12:24:01 PM : Underperform Start Price: $22.61 ONXX Score: -109.35

shorrrttttt

Recs

1
Member Avatar jwakron (74.29) Submitted: 2/9/2007 2:55:49 PM : Outperform Start Price: $12.10 ONXX Score: +289.12

Possible takeover target

Recs

0
Member Avatar genedom (98.17) Submitted: 2/1/2007 2:41:06 AM : Outperform Start Price: $11.90 ONXX Score: +296.01

Bayer's buyout target. $18 is a fair price to sell.

Recs

0
Member Avatar mareadoj (53.43) Submitted: 1/9/2007 3:35:29 AM : Outperform Start Price: $11.60 ONXX Score: +304.23

This company will do so well in the near future

Recs

0
Member Avatar airenInDebt (56.97) Submitted: 12/30/2006 12:57:36 AM : Outperform Start Price: $10.67 ONXX Score: +340.04

I like drugs and I like them cheap. The company makes generic drugs! Yeah they had a set back, but who cares, there's plenty of sick (and not so sick) people who want their drugs!

Recs

1
Member Avatar donklenzman (90.19) Submitted: 12/24/2006 4:05:27 AM : Outperform Start Price: $10.60 ONXX Score: +341.93

Oversold on FDA rejection of liver drug application for skin cancer. Firm has strong sales growth on its current cancer drugs and two major applications in the pipeline.
Bayer is strong partner.

Recs

1
Member Avatar 301002176 (< 20) Submitted: 12/11/2006 1:13:15 AM : Outperform Start Price: $12.47 ONXX Score: +276.16

Recent trial failure is a Buy opportunity. Still many more trials pending.

Recs

1
Member Avatar Tamtalizied (< 20) Submitted: 12/8/2006 11:15:13 PM : Outperform Start Price: $12.47 ONXX Score: +276.16

Buy Low, Sell High

Recs

2
Member Avatar drwings (< 20) Submitted: 10/24/2006 3:56:34 PM : Outperform Start Price: $18.58 ONXX Score: +149.77

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative therapies that target the molecular mechanisms that cause cancer. The company is developing Nexavar®, a small molecule drug, with Bayer Pharmaceuticals Corporation. Nexavar has been approved for the treatment of advanced kidney cancer.

Results 61 - 69 of 69 : « Previous 1 2 3 4

Featured Broker Partners


Advertisement